Why Don't We Have Proven Treatments for HFpEF?
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 28408453.
- Also identified by DOI 10.1161/CIRCRESAHA.116.310119 and PMC identifier 5407384.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The lack of effective treatments for heart failure with preserved ejection fraction (HFpEF) represents a large and growing unmet need in cardiology today. A critical obstacle to therapeutic innovation in HFpEF has been the absence of animal models that accurately recapitulate the complexities of the human disease. Here we propose that more comprehensive multi-organ system and functional phenotyping of preclinical models is essential if we are to maximize our chances of discovering and validating novel targets for effective therapeutic development in HFpEF.
Medical subject headings
- Heart Failure
- Stroke Volume